Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective

MeSH terms

• Antineoplastic Agents, Immunological* / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols
• Carcinoma, Non-Small-Cell Lung* / drug therapy
• Humans
• Lung Neoplasms* / drug therapy
• Neoadjuvant Therapy
• Nivolumab / therapeutic use